Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Pegylated Liposomal Irinotecan"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
James E. Frampton
Publikováno v:
Drugs
Liposomal irinotecan (nal-IRI; Onivyde®; also known as pegylated liposomal irinotecan) has been developed with the aim of maximising anti-tumour efficacy while minimising drug-related toxicities compared with the conventional (non-liposomal) formula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c69bac4a78c8bb1bb909ed0410516f7
https://pubmed.ncbi.nlm.nih.gov/32621123
https://pubmed.ncbi.nlm.nih.gov/32621123
Autor:
Vivian P. Vu, Ernest Groman, Robert I. Scheinman, Halli Benasutti, Laura Saba, Guankui Wang, Dmitri Simberg
Publikováno v:
Bioconjugate Chemistry. 28:2747-2755
Opsonization (coating) of nanoparticles with complement C3 component is an important mechanism that triggers immune clearance and downstream anaphylactic and proinflammatory responses. The variability of complement C3 binding to nanoparticles in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e53c68c2b588dc7b727b0961107e605
https://doi.org/10.1021/acs.bioconjchem.7b00496
https://doi.org/10.1021/acs.bioconjchem.7b00496
Autor:
Emily Chan, Jeffrey R. Infante, Hiroshi Kodaira, Suzanne F. Jones, Whitney P Kirschbrown, Huali Wu, Wooin Lee, Johanna C. Bendell, William C. Zamboni, Mace L. Rothenberg, Beth A. Zamboni, Howard A. Burris, Vicki L. Keedy, Satoshi Ikeda
Publikováno v:
International Journal of Nanomedicine
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective of this study was to evaluate the factors associated with interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 in patients with advanced so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfad1a8f9e76c3c1d46d6e02ba10695e
https://doi.org/10.2147/ijn.s207276
https://doi.org/10.2147/ijn.s207276
Autor:
Joanne McEntee, Eleanor Kotas, Ahmed Abdulla, Daniel H. Palmer, Marty Richardson, Nigel Fleeman, Angela Boland, Angela Stainthorpe, Sophie Beale, Adrian Bagust
Publikováno v:
PHARMACOECONOMICS
BASE-Bielefeld Academic Search Engine
BASE-Bielefeld Academic Search Engine
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Shire Pharmaceuticals) of pegylated liposomal irinotecan hydrochloride trihydrate (liposomal irinotecan) to submit clinical and cost-effectiveness evidence for its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cb372e7fd978e391a668b57cd9c20ed
http://livrepository.liverpool.ac.uk/3013556/1/nal-iri_PE_manuscript_re-submitted_clean.docx
http://livrepository.liverpool.ac.uk/3013556/1/nal-iri_PE_manuscript_re-submitted_clean.docx
Autor:
Vicki L. Keedy, Emily Chan, Wooin Lee, Hiroshi Kodaira, William C. Zamboni, Huali Wu, Johanna C. Bendell, Howard A. Burris, Jeffrey R. Infante, Satoshi Ikeda, Mace L. Rothenberg, Suzanne F. Jones
Publikováno v:
Cancer Chemotherapy and Pharmacology. 70:699-705
IHL-305 is a novel PEGylated liposome containing irinotecan. This study examined the safety profile and pharmacokinetics of IHL-305 and established the maximum tolerated dose and recommended phase II dose (RP2D). In a standard 3 + 3 design, IHL-305 w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c33a78af5b551f242910ec16ea5fe04
https://doi.org/10.1007/s00280-012-1960-5
https://doi.org/10.1007/s00280-012-1960-5
Autor:
Vicki L. Keedy, Howard A. Burris, Emily Chan, Johanna C. Bendell, Satoshi Ikeda, Beth A. Zamboni, Hiroshi Kodaira, Mace L. Rothenberg, Jeffrey R. Infante, Whitney P Kirschbrown, Huali Wu, Wooin Lee, Suzanne F. Jones, William C. Zamboni
Publikováno v:
International Journal of Nanomedicine
Huali Wu,1 Jeffrey R Infante,2 Vicki L Keedy,3 Suzanne F Jones,2 Emily Chan,3 Johanna C Bendell,2 Wooin Lee,4 Whitney P Kirschbrown,1 Beth A Zamboni,5 Satoshi Ikeda,6 Hiroshi Kodaira,6 Mace L Rothenberg,3 Howard A Burris III,2 William C Zamboni1,7–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1578438171b08058c8bbfc79e72e06d
https://pubmed.ncbi.nlm.nih.gov/31413572
https://pubmed.ncbi.nlm.nih.gov/31413572
Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation
Autor:
Na Wei, ChunLei Li, Li Zhang, Li Yongfeng, Xian Xiu, Caixia Wang, JingXia Cui, Lan Zhang, Yanhui Li, Ping Wang
Publikováno v:
The Journal of pharmacy and pharmacology. 63(6)
Objectives Liposomal delivery of irinotecan could provide protection against drug hydrolysis, deliver more active lactone form to tumours and prolong irinotecan exposure time. Nevertheless, conventional drug-loading technologies have typically result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a03ddf5247f2d11fa30fa1f414f9468
https://pubmed.ncbi.nlm.nih.gov/21585373
https://pubmed.ncbi.nlm.nih.gov/21585373
Autor:
Suzanne F. Jones, Howard A. Burris, Johanna C. Bendell, Emily Chan, Huali Wu, Beth A. Zamboni, Hiroshi Kodaira, Satoshi Ikeda, Vicki L. Keedy, Jeffrey R. Infante, William C. Zamboni
Publikováno v:
Molecular Cancer Therapeutics. 8:C127-C127
Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL-305 is a PEGylated-liposomal formulation of CPT-11. The PK of liposomal agents is highly complex due to the variability in the disp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e32b62fa610351eac78762480f33d534
https://doi.org/10.1158/1535-7163.targ-09-c127
https://doi.org/10.1158/1535-7163.targ-09-c127
Autor:
J. R. Infante, Mace L. Rothenberg, Vicki L. Keedy, S. Ikeda, H. A. Burris, Emily Chan, William C. Zamboni, W. Lee, Siân Jones, Johanna C. Bendell
Publikováno v:
Journal of Clinical Oncology. 27:2547-2547
2547 Background: Irinotecan (CPT-11) is a prodrug of SN-38 that has antitumor activity in a wide range of solid tumors. IHL- 305 is a PEGylated-liposomal formulation of irinotecan designed to increase the therapeutic index by prolonging the duration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f948bf83ea28ced0a2ce61a8391e344
https://doi.org/10.1200/jco.2009.27.15_suppl.2547
https://doi.org/10.1200/jco.2009.27.15_suppl.2547